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MicroRNAs (miRNAs) are non-coding RNAs, approximately 22 nucleotides in length that act as 
post-transcriptional regulators. Thousands of miRNAs have been identified in animals, and they are well 
conserved across species. MicroRNAs play essential regulatory roles in cellular processes, and changes in 
miRNA expression are associated with human diseases. Originally, miR-124 was identified as a brain-enriched 
miRNA and shown to be involved in brain and neuronal development. MiR-124 has since been reported to be 
expressed in other organs and to be involved in various biological phenomena. MiRNA-124 plays roles in various 
pathologic conditions, including cancers, acute stress, cardiovascular disorders, inflammatory responses, chronic 
pain, and osteoclast differentiation. MiR-124 has also been shown to suppress various tumor functions, including 
proliferation, activation, survival, invasion, metastasis, and migration. Rheumatoid arthritis (RA) is a chronic 
auto-inflammatory disorder of unknown etiology, whose treatment has been significantly improved by the 
advent of biological drugs. Even so, some RA patients show little or no response to these therapies, suggesting 
the need for additional treatments. In a study comparing miRNA expression in RA and osteoarthritis (OA) 
fibroblast-like synoviocytes (FLS), we found that miR-124a was the only miRNA whose expression was lower in 
RA than in OA FLS. MiR-124a was found to directly downregulate the production of CDK-2 and MCP-1. In the 
rat adjuvant-induced arthritis (AIA) model, a single injection of pre-miR-124 into one ankle joint suppressed 
joint swelling in all of the limbs. Histological examination showed that AIA rats treated with pre-miR-124 
exhibited reduced synoviocyte proliferation, less leucocyte infiltration into synovial tissue, and less cartilage and 
bone destruction than untreated AIA rats. The joints of the pre-miR-124-treated AIA rats also showed reduced 
osteoclast numbers and reduced RANKL, integrin β1 (ITGB1), and NFATc1 expression levels. MiR-124 was 
shown to directly target the 3’UTRs of the rat NFATc1, ITGB1, SP1, and CEBPα mRNAs. Both miR-124 and 
miR-124a were also found to directly target human NFATc1 mRNA and to suppress the differentiation of 
human osteoclasts from monocytes. Taken together, recent studies suggest that MiR-124 may be a promising 
therapeutic agent for RA and other diseases. 
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MiRNA biogenesis 
MicroRNAs (miRNAs) are short, ∼22-nucleotide-long 
non-coding RNAs that act as post-transcriptional regulators 
[1]. Thousands of miRNAs have been identified in animals, 
and they are well conserved across species. MiRNAs are first 
transcribed as pri-miRNAs by RNA polymerase II and are 
derived from individual miRNA genes or from introns, 
intergenic regions, or polycistronic transcripts [2, 3]. 
Pri-miRNAs, generally several thousand bases long, are 
processed in the nucleus by the RNase III enzyme Drosha 
into 70-100-nucleotide-long, hairpin-shaped precursors, 
called pre-miRNAs [4]. Pre-miRNAs are then exported from 
the nucleus to the cytoplasm, where the RNA endonuclease 
Dicer mediates their processing to generate double-stranded 
miRNAs [5]. The miRNA duplex is incorporated into a 
multicomponent protein complex known as the 
RNA-induced silencing complex (RISC). During this 
process, one strand of the miRNA duplex is selected as the 
mature miRNA, which guides the RISC complex to the 
3’-UTR of target mRNAs [6]. MiRNAs usually bind to 
imperfect complementary sites in their target mRNAs. The 5’ 
portion of a miRNA spanning bases two-eight, termed the 
seed region, is especially important for target recognition. [7]. 
MiRNAs silence gene expression via at least three 
mechanisms: translation inhibition, translation initiation 
inhibition, and target mRNA destabilization [1]. Each miRNA 
is predicted to regulate hundreds of different mRNAs, and 
miRNAs in general are predicted to control the expression of 
~50% of the protein-coding genes, and to contribute to the 
regulation of multiple cellular processes. With the potential 
to target hundreds of different mRNAs via imperfect binding 
of target genes, miRNAs act to coordinate or fine-tune the 
expression of proteins to achieve physiologically optimal 
levels [8]. In neuroblastomas, for example, there are ~1,250 
mRNAs whose expression is inversely correlated with at 
least one miRNA, and cross-talk between miRNAs and 
epigenetic regulatory mechanisms have been shown to play a 
role in neuroblastoma cell differentiation [9]. MiRNAs are 
expressed in a tissue-specific or developmental/stage-specific 
manner, at which they can regulate a large number of cellular 
processes. The changes of expression of miRNAs might 
influence to the development of many human diseases.  
MiR-124 
MiR-124 is a highly conserved miRNA that is abundantly 
expressed in the brain and spinal cord of humans, fish, mice, 
and flies [10]. Human mature miR-124 is produced from three 
pre-miRNAs, pre-miR-124-1, pre-miR-124-2, and 
pre-miR-124-3, which are derived from separate 
chromosomal locations, 8p23.1, 8p12.3, and 20q13.33, 
respectively, and are transcribed at different levels. MiR-124 
was initially identified as has-miR-124a, with the sequence 
UUAAGGCACGCGGUGAAUGCCA, and was registered in 
miRBase, a public database [11, 12]. The revised sequence is 
identical to the original one, but is missing the 5’ and 3’ 
terminal nucleotides [13], and is referred to as has-miR-124 in 
miRBase, version 10.  
Regulation of miR-124 
The regulation of miR-124 expression is only partially 
understood. Nicotine is reported to upregulate miR-124 
expression by activating the α7-nicotinic acetylcholine 
receptor (α7nAChR) in murine macrophages [14]. In addition, 
either morphine or the inhibition of acetylcholine receptor 
signaling significantly promotes miR-124 upregulation in 
murine bone marrow-derived macrophages or microglia. In 
these cases, NF-κB p65 binds directly to the promoters of 
pri-miR-124-1 and pri-miR-124-3 in mice, resulting in 
miR-124 upregulation [15]. The same study also showed that 
c-Fos overexpression in BV2 microglial cells significantly
inhibits miR-124 expression, while the siRNA-mediated
inhibition of cAMP response element binding protein
(CREB) induces miR-124 expression [15]. Notably, c-Fos and
CREB are transcription factors that also regulate the
expression of osteoclast-specific genes [16].
We recently found that miR-124 is not expressed in E11 
cells, a cell line established from human rheumatoid synovial 
fibroblasts by transformation with SV40 large T antigen. In 
this cell line, the CpG islands in the putative promoters of 
pre-miR-124-1, pre-miR-124-2, and pre-miR-124-3 are 
methylated, and miR-124 expression is induced when the 
cells are treated with histone deacetylase inhibitors 
(unpublished data). In addition, Lujambio et al. found that 
the CpG islands in the putative promoters of these 
pre-miR-124s are methylated in human cancer cells [17].  
MiR-124 and neuronal development 
MiR-124 is a brain-enriched miRNA that contributes to 
physiological neural development by degrading non-neuronal 
transcripts [18, 19]. The polypyrimidine tract binding protein 1 
(PTBP1) mRNA, which encodes a global repressor of 
alternative brain-specific pre-mRNA splicing in 
non-neuronal cells, is a target of miR-124 [20]. The blockage 
of miR-124 expression in mature neurons leads to a selective 
increase in non-neuronal transcripts [21], while an increase in 
miR-124 expression in non-neuronal cells results in a shift 
toward neuronal cell-specific gene expression [22]. 
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Regulation of acute stress and inflammation by miR-124 
Several studies indicate that miR-124 suppresses acute 
stress and inflammatory responses. The p38-alpha to -delta 
mitogen-activated protein kinases (MAPKs) are central 
regulatory molecules that coordinate acute stress and 
inflammatory responses. The expression of p38-alpha protein 
is directly suppressed by miR-124 in the brain [23]. In 
experimental autoimmune encephalomyelitis (EAE), 
miR-124 is downregulated in the activated microglia. The 
overexpression of miR-124 in macrophages directly inhibits 
expression of the transcription factor, 
CCAAT/enhancer-binding protein-alpha (CEBP), resulting 
in the downregulation of its downstream target PU.1 and 
reduced macrophage activity. The peripheral administration 
of miR-124 into EAE mice causes systemic macrophage 
deactivation and reduced myelin-specific T cell activation, 
resulting in marked disease suppression [24]. In a recent study, 
morphine was shown to suppress innate immune responses in 
microglia and macrophages through the differential 
regulation of Toll-like receptors (TLRs) and 
acetylcholinesterase. Morphine induces the expression of 
MiR-124, which directly inhibits expression of the NF-κB 
subunit p65 and of TNFR-associated factor 6 (TRAF6) [16]. 
The vagal nerve has been shown to control the inflammatory 
response through a “cholinergic anti-inflammatory pathway” 
that is mediated by the α7-nicotinic acetylcholine receptor 
(α7nAChR) on macrophages. The treatment of LPS-exposed 
cells or mice with cholinergic agonists results in the 
upregulation of MiR-124, which in turn modulates 
lipopolysaccharide (LPS)-induced cytokine production, by 
directly targeting Signal transducer and activator of 
transcription 3 (STAT3) to decrease IL-6 production and 
TNF-α converting enzyme (TACE) to reduce TNF-α release 
[15]. These findings suggest that miR-124 is an important 
anti-inflammatory mediator.  
Role of miR-124 in regulating chronic pain 
MiR-124 is also known to regulate chronic pain. 
Microglia/macrophages in the spinal cord play key roles in 
the development of chronic pain. The microglial levels of G 
protein-coupled receptor kinase 2 (GRK2) are reduced in 
models of chronic pain. In LysM-GRK2+/− mice, which 
exhibit an ~50% reduction in GRK2 levels in the 
microglia/macrophages, prolonged inflammatory 
hyperalgesia develops concomitantly with ongoing spinal 
microglial activation. In these mice, IL-1 induces a 
transition from acute to persistent hyperalgesia, which is 
associated with reduced spinal cord microglia miR-124 
levels and a switch toward a pro-inflammatory M1 
microglia/macrophage phenotype, together with increased 
pro-inflammatory cytokine production. The treatment of 
these mice with miR-124 prevents the IL-1-induced 
transition to persistent hyperalgesia and normalizes the 
expression of spinal M1/M2 markers [25].  
MiR-124 and bone metabolism 
Lee et al. recently showed that miR-124 also regulates the 
osteoclastogenesis of murine bone marrow macrophages by 
directly suppressing the nuclear factor of activated T cell 
cytoplasmic 1 (NFATc1) expression [26]. They also found 
that the overexpression of constitutively active NFATc1 
prevents the miR-124-mediated inhibition of 
osteoclastogenesis. Moreover, miR-124 suppresses the 
proliferation and motility of osteoclast precursors, and the 
reduced motility of the osteoclast precursors is associated 
with reduced RhoA and Rac1 expression. In addition, 
Okamoto et al. reported that miR-124 is an important 
regulatory factor involved in the osteoblastic differentiation 
of murine iPS cells [27]. Thus, miR-124 is emerging as a key 
regulator of bone formation, with roles in both osteoclastic 
and osteoblastic differentiation. 
MiR-124 and cancer regulation 
MiR-124 is a potential tumor suppressor and an 
independent prognostic marker in many cancers, including 
colorectal [28] and prostate cancer [29]. The loss of miR-124 
expression is a common event in prostate cancer, and the 
restoration of miR-124 expression inhibits prostate cancer 
cell growth by directly targeting the androgen receptor and 
inducing p53 upregulation [29]. In addition, miR-124 directly 
suppresses STAT3 expression, resulting in the increased 
apoptosis and reduced growth of colorectal cancer cells [30]. 
The mechanism of hepatocellular carcinoma (HCC) was 
recently shown to involve a positive feedback loop consisting 
of the IL-6 receptor, STAT3, miR-24, miR-629, hepatocyte 
nuclear factor 4-alpha (HNF4-), and miR-124. HNF4- is a 
member of the nuclear receptor family of ligand-dependent 
transcription factors, and its downregulation promotes HCC 
initiation. HCC cells and tumors exhibit increased levels of 
miR-24 and miR-629, each of which directly inhibits 
HNF4- expression, which leads to reduced miR-124 
expression. Since the IL-6 receptor is a direct target of 
miR-124, the reduced HNF4- expression results in 
increased IL-6 receptor expression, which promotes STAT3 
phosphorylation. The presence of STAT3-binding sites in the 
promoters of miR-24 and miR-629 complete the positive 
feedback loop, to maintain hepatocyte transformation and 
induce HCC progression. Notably, the systemic 
administration of miR-124 suppresses HCC in an animal 
model, suggesting that this agent may have the potential for 
treating human liver cancer [31]. MiR-124 also directly 
reduces the expression of phosphoinositide 3-kinase catalytic 
RNA & DISEASE 2017; 4: e1252. doi: 10.14800/rd.1252; © 2017 by Yuji Nakamachi, et al.
http://www.smartscitech.com/index.php/rd 
Page 4 of 7 
subunit alpha (PIK3CA), and the treatment of HCC cells 
with miR-124 was found to inhibit the PI3K/Akt pathway, 
resulting in reduced cell survival and proliferation [32]. In a 
separate study, miR-124 was shown to directly suppress the 
expression of two oncogenes, Rho-associated protein kinase 
2 (ROCK2) and Enhancer of zeste homolog 2 (EZH2). The 
expression level of miR-124 is frequently reduced in HCC 
cells and tissues, and a low miR-124 expression level is 
significantly associated with a more aggressive and/or poor 
prognostic phenotype of patients with HCC [33]. In breast 
cancer, miR-124 directly targets the epithelial mesenchymal 
transition (EMT) regulator Slug, which is an E-cadherin 
transcription repressor. MiR-124 levels are frequently 
reduced in breast cancer cells, and the restoration of miR-124 
expression in these cells increases the expression of 
E-cadherin, a repressor of cell invasion and metastasis [34]. 
MiR-124 directly regulates the cell cycle dependent kinase 6 
(CDK6) expression in medulloblastoma, and the treatment of 
medulloblastoma cells with miR-124 results in significantly 
decreased cell growth and reduced CDK6 expression [35]. 
MiR-124 also downregulates integrin β1 (ITGB1) in oral 
squamous cell carcinoma cells, and the introduction of 
MiR-124 into these cells reduces their adherence and motility 
[36]. In B-cell lymphomas, miR-124 directly targets NF-κB 
p65, and the introduction of miR-124 into these cells 
suppresses MYC and BCL2, and inhibits cell proliferation 
and survival [37]. 
Mir-124 and pulmonary arterial smooth muscle 
The abnormal proliferation and differentiation of 
pulmonary arterial smooth muscle cells (PASMCs) 
contributes to the pathogenesis of cardiovascular disorders. 
Hypoxia results in the down-regulation of miR-124 in human 
PASMCs, consistent with the activation of NFAT during this 
process. In human PASMC, miR-124 directly regulates 
multiple target genes, including a component of the NFAT 
pathway, NFATc1, and two regulators of NFAT signaling, 
calmodulin-binding transcription activator 1 (CAMTA1) and 
PTBP1. MiR-124 overexpression inhibits PASMC 
proliferation and prevents phenotypic changes [38]. The 
miR-124 expression is also reduced in fibroblasts isolated 
from patients with severe pulmonary hypertension. The 
overexpression of miR-124 significantly attenuates the 
proliferation, migration, and expression of monocyte 
chemotactic protein-1 (MCP-1) in the activated fibroblasts. 
In addition to targeting MCP-1 in these cells, MiR-124 
targets the alternative splicing factor, PTBP1, and MiR-124 
overexpression results in reduced PTBP1 expression and the 
subsequent regulation of Notch1/phosphatase, tensin 
homolog/FOXO3/p21Cip1, and p27Kip1 signaling. 
Furthermore, miR-124 expression is suppressed by histone 
deacetylases, and the treatment of activated fibroblasts with 
histone deacetylase inhibitors increases the miR-124 
expression [39].  
RA Pathogenesis 
RA is a chronic inflammatory disorder of unknown 
etiology that is associated with progressive disability, 
systemic complications, early death, and high socioeconomic 
costs. RA occurs in 0.5-1.0% of the adult population 
worldwide [40]. RA patients present with joint swelling and 
pain, associated with synoviocyte hyperplasia, which if left 
untreated, leads to pannus formation and the destruction of 
bone and cartilage [41]. T cells, B cells, dendritic cells, and 
other leucocytes infiltrate the rheumatoid synovial tissue, 
where they produce cytokines and chemokines that cause 
many of RA’s pathological and clinical manifestations [41]. 
Three prominent cytokines associated with RA, interleukin 
(IL)-17, IL-6, and TNF-alpha, enhance local inflammation, 
which further increases the production of inflammatory 
mediators. IL-6, in particular, activates the JAK-STAT3 
pathway [40, 42]. Various cytokines induce the expression of 
receptor activator for nuclear factor kB ligand (RANKL) on 
osteocytes and other mesenchymal cells that support 
osteoclastogenesis [40, 43]. RANKL specifically and strongly 
induces the expression of NFATc1, which is the master 
regulator of osteoclast differentiation [44]. NFATc1 
cooperates with other transcription factors to regulate a 
number of osteoclast-specific genes that have roles in 
osteoclastogenesis and bone loss [42]. 
RA treatment strategies 
The current recommendations for RA treatment involve 
the early initiation and long-term administration of 
conventional, synthetic disease modifying anti-rheumatic 
drugs (csDMARDs), including the commonly used 
csDMARD, methotrexate (MTX) [45, 46]. For patients with 
inadequate responses to csDMARDs or who initially 
demonstrate high disease activities, biologic DMARDs 
(bDMARDs), also called “biologics,” which target 
TNF-alpha, IL-6, and T cells, are recommended as either 
add-on or independent treatments to achieve better disease 
control [45, 46]. In the current “biologics era” of RA treatment 
“treat to target” (T2T) is a new treatment strategy, in which 
patients are treated to achieve either disease remission or 
low-disease activity. Although this strategy has greatly 
improved the outcomes for many RA patients, some patients 
remain non- or only partially responsive to current 
treatments. Because biologics or combination treatments do 
not work for all RA patients, and yet are very costly, 
additional therapies that are more efficacious for this group 
of patients are needed [47].  
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MiR-124 and RA 
We previously reported that five miRNAs (miR-146a, 
miR-223, miR-142-3p, miR-142-5p, and miR-133a) are 
expressed more strongly in RA than in OA FLS. In contrast, 
MiR-124a is the only miRNA whose expression is reduced in 
RA compared with OA FLS. The transfection of precursor 
(pre)-miR-124a into RA FLS significantly suppresses FLS 
proliferation by arresting the cell cycle in the G1 phase and 
suppressing the secretion of MCP-1. Furthermore, miR-124a 
directly affects the production of both CDK-2 and MCP-1 by 
regulating the translation of their mRNAs [48]. We 
investigated the in vivo effects of miR-124 on inflammation 
using the rat adjuvant induced arthritis (AIA) model [49]. The 
endogenous expression of miR-124 in the ankle joints of 
AIA rats was found to be significantly lower than that in the 
ankle joints of non-AIA rats. Pre-miR-124 injection into the 
right ankle significantly elevated the miR-124 in that ankle 
and slightly elevated it in the left ankle of AIA rats. Notably, 
a single injection of pre-miR-124 into one ankle joint was 
found to suppress arthritis in all four paws. A comparison of 
body weights in the treated and non-treated mice indicated 
that the pre-miR-124 treatments were not associated with any 
apparent systemic toxicity. Histopathological analysis of the 
ankles revealed that the synoviocyte proliferation, leucocyte 
infiltration into synovial tissue, and the destruction of 
cartilage and bone were all improved in the AIA rats treated 
with pre-miR-124. Furthermore, micro-CT analysis revealed 
that miR124 attenuates the bone destruction in AIA rats, and 
tartrate-resistant acid phosphatase (TRAP) staining of the 
ankle joints revealed that miR-124 reduces osteoclast 
differentiation. RANKL, which is essential for osteoclast 
differentiation and activation, was found to be significantly 
suppressed in the ankles of AIA rats treated with 
pre-miR-124. Next, we analyzed the target genes of rat 
miR-124 using luciferase assays, and found that NFATc1, 
ITGB1, specificity protein 1 (Sp1), and CEBP are all 
regulated by miR-124. The NFATc1 and ITGB1 protein 
levels were found to be reduced in the ankle tissues of the 
pre-miR-124-treated AIA rats. Notably, the 
ITGB1-expressing cells were found to be TRAP-positive 
osteoclasts. Thus, our studies revealed that treating rats with 
pre-miR-124 suppresses the development of AIA and 
directly reduces osteoclast differentiation (Figure 1). 
Conclusions 
Recent studies indicate that miR-124 is involved in the 
Figure 1. Target molecules of miR-124 in rat adjuvant-induced arthritis. ITGA1: integrin 1, 
ITGB1: integrin β1, IL7R: interleukin-7 receptor, RANKL: receptor activator of nuclear factor kappa-B 
ligand, NFTAc1: nuclear factor of activated T-cells cytoplasmic 1, CEBPA: CCAAT/enhancer-binding 
protein alpha, AP-1: activator protein 1, MITF: microphthalmia-associated transcription factor, PU.1: 
spleen focus forming virus proviral integration oncogene, SPI1, CDK2: cyclin-dependent kinase 2, 
SP1: Specificity protein 1. 
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pathogenesis of cancers, acute stress, cardiovascular 
disorders, inflammatory responses, chronic pain, and 
osteoclast differentiation. MiR-124 levels are suppressed in 
RA tissue, and the treatment of AIA rats with pre-miR-124 
suppresses the progression of joint damage. Thus, miR-124 is 
a potential therapeutic target for RA and other diseases. 
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